Stockscreener 앱 받기
6.35
0.78%
-0.05
전일 마감가:
$6.40
열려 있는:
$6.36
하루 거래량:
1,768
Relative Volume:
0.02
시가총액:
$1.08B
수익:
$163.13M
순이익/손실:
$-34.75M
주가수익비율:
-12.33
EPS:
-0.5152
순현금흐름:
$-231.66M
1주 성능:
+2.75%
1개월 성능:
-3.35%
6개월 성능:
+64.08%
1년 성능:
-29.98%
1일 변동 폭
$6.28
$6.36
1주일 범위
$6.28
$6.5399
52주 변동 폭
$3.62
$9.50
발네바 Stock (VALN) Company Profile
VALN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VALN
Valneva Se Adr
|
6.36 | 542.50M | 163.13M | -34.75M | -231.66M | -0.5152 |
|
ONC
Beone Medicines Ltd Adr
|
245.44 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.91 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.39 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.25 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
500.70 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
발네바 Stock (VALN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-08-03 | 개시 | H.C. Wainwright | Buy |
발네바 주식(VALN)의 최신 뉴스
Valneva SE earnings missed by $0.01, revenue topped estimates - Investing.com
Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - Louisiana First News
Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SEVALN - Louisiana First News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teleflex Incorporated - GlobeNewswire Inc.
Valneva SE Company Investigated by the Portnoy Law Firm - GlobeNewswire
Valneva shares leap on Brazilian approval of chikungunya vaccine By Investing.com - Investing.com India
Valneva shares leap on Brazilian approval of chikungunya vaccine - Investing.com Australia
VALN Doses First Infant With Shigella Vaccine in Mid-Stage Study - MSN
VALN Doses First Infant With Shigella Vaccine In Mid-Stage Study - Barchart.com
H.C. Wainwright maintains Buy on Valneva with $17 price target - Investing.com
Valneva SE ADR’s Banking’s 100-Day Moving Average at 5.61: Will the Stock Break Through? - investchronicle.com
The Schall Law Probes Valneva Over Vaccine Safety Concerns - Lawyer Monthly
VALN Investors Have Opportunity to Join Valneva SE Fraud Investigation with the Schall Law Firm - PR Newswire
Valneva SE earnings missed by $0.32, revenue fell short of estimates - Investing.com India
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Stockholders to Learn More About the Investigation - markets.businessinsider.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Valneva SE (VALN) And Encourages Shareholders to Reach Out - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Shareholders to Learn More About the Investigation - Markets Insider
Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Encourages Valneva SE (VALN) Shareholders to Inquire about Securities Investigation - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Is Investigating Valneva SE (VALN) And Encourages Investors to Connect - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Encourages Valneva SE (VALN) Stockholders to Inquire about Securities Investigation - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Investors to Learn More About the Investigation - Markets Insider
Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Is Investigating Valneva SE (VALN) And Encourages Stockholders to Connect - markets.businessinsider.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Stockholders to Learn More About the Investigation. - Markets Insider
ATTENTION VALN SHAREHOLDERS: Investors who lost money on Valneva SE are urged to contact Levi & Korsinsky about an ongoing investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Valneva SE (VALN) Investors to Inquire about Securities Investigation - Markets Insider
Press Release Distribution & PR Platform - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Valneva SE (VALN) And Encourages Investors to Reach Out - Markets Insider
H.C. Wainwright cuts Valneva stock target to $17, maintains Buy By Investing.com - Investing.com South Africa
H.C. Wainwright cuts Valneva stock target to $17, maintains Buy - Investing.com
Déclaration d'actions et de droits de vote de la société Valneva SE - GlobeNewswire Inc.
Valneva stock holds $18 target on UK vaccine nod - Investing.com
Favorable VLA1553-321 Phase 3 Study Results Boost VALN Stock - Yahoo Finance
VALNEVA - GlobeNewswire Inc.
Chikungunya Vaccine Label Extension Call Likely to Support VALN Stock - Yahoo Finance
발네바 (VALN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.76%
0.89%
자본화:
|
볼륨(24시간):